Intervention Review

You have free access to this content

Maintenance chemotherapy for ovarian cancer

  1. Ling Mei1,
  2. Hui Chen1,
  3. Dong Mei Wei1,
  4. Fang Fang1,*,
  5. Guan J Liu2,
  6. Huan Yu Xie3,
  7. Xun Wang1,
  8. Juan Zou1,
  9. Xu Han1,
  10. Dan Feng4

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 29 JUN 2013

Assessed as up-to-date: 21 NOV 2012

DOI: 10.1002/14651858.CD007414.pub3


How to Cite

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD007414. DOI: 10.1002/14651858.CD007414.pub3.

Author Information

  1. 1

    West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  2. 2

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu, Sichuan, China

  3. 3

    People's Hospital of Deyang City, Department of Obstetrics and Gynecology, Deyang, Sichuan, China

  4. 4

    Cheng du Women & Children’s Central Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

*Fang Fang, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. ffmn59@163.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 29 JUN 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Bolis 2006 {published data only}
Cheng 2006 {published data only}
  • Cheng NH, Huang HF, Pan LY, Shen K, Wu M, Yang JX. Consolidation chemotherapy in advanced epithelial ovarian carcinoma:a prospective randomized controlled trial. Medical Journal of Chinese People's Liberation Army 2006;31(7):654-6.
Mannel 2011 {published data only}
  • Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecology Oncology 2011;122(1):89-94.
Nicoletto 2004 {published data only}
  • Nicoletto MO, Tumolo S, Falci C, Donach M, Visona E, Rosabian A, et al. A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission?. International Journal of Medical Sciences 2004;1(2):116-25.
Pecorelli 2009 {published data only}
  • Pecrelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Journal of Clinical Oncology 2009;27(28):4642-8.
Piccart 2003 {published and unpublished data}
  • Piccart MJ, Floquet A, Scarfone G, Willemse PHB, Emerich J, Vergote I, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase 3 study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International Journal of Gynecologic Cancer 2003;13(suppl 2):196-203.
Placido 2004 {published and unpublished data}
  • Placido SD, Scambia G, Vagno GD, Naglieri E, Lombardi VA, Biamonte R, et al. Toptecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology 2004;22(13):2635-42.
Sorbe 2003 {published data only}
  • Sorbe B. Consolidation treatment of advanced (FIGO stage 3) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. International Journal of Gynecologic Cancer 2003;13(3):278-86.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Abaid 2010 {published data only}
  • Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV, Markman M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology 2010;78(5-6):389-93.
Cure 2001 {published data only}
  • Cure H, Battista C, Guastalla JP, Fabbro M, Tubiana-Mathieu N, Bourgeois H, et al. Phase 3 randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC/Italy study. Proceedings of American Society of Clinical Oncology. 2001.
Lesnock 2011 {published data only}
  • Lesnock JL, Farris C, Krivak TC, Smith KJ, Markman M. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecology Oncology 2011;122(3):473-8.
Mannel 2010 {published data only}
  • Mannel R, Brady M, Kohn E, Hanjani P, Hiura M, Lee R, et al. Gynecologic Oncology.Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. March 2010; Vol. 116:S2.
Markman 2003 {published data only}
  • Markman M, Liu PY, Wilczynski S, Mank B, Copeland LJ, Alvarez RD, et al. Phase 3 randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. Journal of Clinical Oncology 2003;21(13):2460-5.
Markman 2009 {published data only}
  • Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecology Oncology 2009;114(2):195-8.
Scarfone 2002 {published data only}
  • Scarfone G, Merisio C, Garavaglia E, Richiardi G, Tateo S, D'Agostino S, et al. A phase 3 trial of consolidation versus NIHL (NIL) for advanced epithelial ovarian cancer (AEOC) after complete remission (CR). Proceedings of American Society of Clinical Oncology. 2002.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
NCT00108745 {published data only}
  • NCT00108745. Paclitaxel or polyglutamate paclitaxel or observation in treating women with stage III or stage IV ovarian epithelial or peritoneal cancer. http://clinicaltrials.gov/show/NCT00108745.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Bertelsen 1993
  • Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology 1993;49(1):30-6.
GLOBOCAN 2002
  • Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase 2004; 2004; Vol. (No.5. version 2.0).
Hakes 1992
  • Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology 1992;45(3):284-8.
Higgins 2002
Higgins 2009
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from http://www.cochrane-handbook.org/.
Kikuchi 2005
Lambert 1997
  • Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Annals of Oncology 1997;8:327-33.
Ozols 2004
  • Ozols RF. Maintenance chemotherapy standard care. American Society of Clinical Oncology. 2004.
Ozols 2006
Poveda 2003
Stuart 2003
Thigpen 2004
Varia 2003
  • Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:2849-55.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Mei 2010